When CAM is added to standard therapies, survival rates drop, observational study finds May 29, 2026Vol.52 No.21By Jacquelyn Cobb
Trials & Tribulations As rural cancer disparities persist, aligning policy with care delivery models can close the gap May 29, 2026Vol.52 No.21By Matthew L. Anderson
FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applicationsCritics say policies clear the way for major tobacco companies to enter fruit-flavored vape market May 15, 2026Vol.52 No.19By Sara Willa Ernst
Problem: Misinformation and stigma prevent uptake of HPV vaccines and screening. Solution: A comic book April 24, 2026Vol.52 No.16By Jacquelyn Cobb
Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Trials & Tribulations Protecting the cure: Why the future of radiation oncology must be precision-guided April 10, 2026Vol.52 No.14By J. Isabelle Choi
FreeTrials & Tribulations Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients March 27, 2026Vol.52 No.12By W. Kimryn Rathmell
Colorectal cancer is now the leading cause of cancer death in patients under 50Why aren’t 45-year-olds getting their recommended CRC screenings? March 27, 2026Vol.52 No.12By Sara Willa Ernst
Trials & Tribulations Why infection and immunity matter for Florida’s cancer patients February 13, 2026Vol.52 No.06By Eduardo Sotomayor
FreeTrials & Tribulations Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore January 30, 2026Vol.52 No.04By Les Biller
